top of page

FDA Regulatory Strategy & Consulting for IND, NDA, and ANDA Submissions

Axentra Pharma offers unparalleled expertise in global compliance solutions, including fsvp compliance audit services. Our team ensures your product meets FDA and EMA standards, reducing delays and streamlining approval processes. With tailored strategies and robust audits, we help you align with international regulations for seamless market entry. Let Axentra Pharma guide you to success with our trusted fsvp compliance audit services.

Global Regulatory Pathway Design & Market Entry Strategy

Axentra develops tailored regulatory pathways for U.S., EU, UK, Australia, and Canada based on product type, formulation complexity, therapeutic area, and data maturity. We determine the most efficient route for IND, NDA, ANDA, hybrid generic, 505(b)(2), or global MAA submissions and clarify what scientific and CMC evidence is needed at each milestone.

Our strategy integrates:

  • clinical development planning (Phase 1–3 expectations)

  • bioequivalence/biosimilarity strategy where applicable

  • CMC and GMP readiness checkpoints

  • global alignment with ICH, EMA, and MHRA requirements

  • risk identification and mitigation early in development

  • planning for complex dosage forms: sterile, ophthalmic, inhalation, injectables

This ensures every project moves forward with a roadmap that is realistic, efficient, and regulator-ready.

Development Risk Assessment, Regulatory Intelligence & Readiness Planning

Strong regulators look not only at data—but at how well a company anticipates risk.
Axentra brings deep expertise in identifying development and approval risks before they become deficiencies, cost escalations, or complete responses.

We provide:

  • scientific and regulatory gap assessments

  • CMC and GMP alignment checks

  • regulatory impact assessments

  • competitor and RLD strategic analysis

  • indication- and market-specific risk profiling

  • readiness reviews before major milestones (pre-IND, BE study, bio-waiver strategy, manufacturing readiness)

This reduces avoidable delays and strengthens the reliability of your global submission plan.

Regulatory Meetings, Briefing Packages & Authority Engagement

Axentra manages all preparation and execution for regulatory interactions with FDA, EMA, MHRA, Health Canada, and TGA.

Our support includes:

  • strategy and authorship of briefing packages

  • structuring key scientific questions for agencies

  • preparing teams for agency meetings

  • drafting regulatory communications

  • managing follow-up and clarification cycles

  • developing persuasive regulatory arguments based on precedent and guidance

We support:

  • FDA: Pre-IND, Type B/C, Pre-NDA

  • EMA: Scientific Advice

  • MHRA: Innovation Office & Scientific Advice

  • Canada/TGA: Pre-submission consultations

This service strengthens your credibility and prepares your team for confident, well-structured interactions with regulators worldwide.

Why Choose Axentra for Regulatory Strategy & Consulting

Risk-Based Global Pathway Design That Reduces Approval Delays

We create tailored, scientifically grounded regulatory pathways for IND, NDA, ANDA, hybrid generics, and multi-region submissions—identifying approval risks early and aligning development plans with FDA, EMA, MHRA, TGA, and Health Canada expectations.

Deep Cross-Functional Expertise Bridging Clinical, CMC, and GMP Requirements

Axentra integrates regulatory intelligence with real-world development constraints, ensuring your clinical, CMC, and manufacturing plans are synchronized with global regulatory standards and inspection readiness.

Strategic Regulatory Engagement & High-Impact Agency Communication

​We prepare clear, authoritative briefing packages and guide your team through FDA Type B/C meetings and global scientific advice sessions—ensuring your regulatory arguments are well-structured, persuasive, and aligned with precedent.

bottom of page